> Here is an important reminder:  Sinovac's 2nd Q Financial Results:

> - Reaffirmation of 2009 sales projection to be $55 million to $60
> million -
> - H1N1 vaccine may drive additional growth -

> BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:
> SVA), a leading developer and provider of vaccines in China, announced
> today its unaudited financial results for the three-month and six-
> month periods ended June 30, 2009.

>   Financial Highlights

>     -- Sales for the quarter increased 21% to $20.0 million
>     -- Sales for the six-month period increased 5% to $26.6 million
>     -- Operating income for the quarter rose 52% to $10.7 million
>     -- Operating income for the six-month period increased 11% to
>        $11.3 million.
>     -- Net income attributable to the shareholders increased 74% to
>        $5.8 million in the second quarter, with diluted EPS of $0.14
>     -- Cash and cash equivalents at June 30, 2009 was $46.7 million.

> Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
> "We are very pleased with our second quarter results, with sales up
> 21% and net income up 74%. Our revenue growth in the quarter was
> partly driven by increased sales of our inactivated hepatitis A
> vaccine, Healive®, to the public market, as we worked to fulfill the
> previously announced purchase order from China's Ministry of Public
> Health (MOH). Sinovac fulfilled and recorded 89% of the original order
> for $12.8 million worth of doses in the second quarter of 2009. Going
> forward, we will continue to focus on increasing our penetration of
> both the private and public markets.

> Mr. Yin continued, "We remain very excited about our growth prospects
> for 2009 and beyond. In addition to the H1N1 vaccine, we have a robust
> pipeline of other investigational vaccines, including enterovirus 71
> (EV 71), pneumococcal conjugated vaccine, and Japanese encephalitis.
> Overall, our objective for the next three to five years is to have one
> or two product candidates per year entering into clinical trials
> beginning in 2010 and one or two products launched into the market per
> year commencing in 2012. In addition to our organic growth strategy,
> we have the financial flexibility to selectively pursue acquisition
> candidates that will help to expand our product pipeline, due to $47
> million of cash and cash equivalents on our balance sheet. Previously,
> we projected revenues of $55 million to $60 million for the full year
> 2009. Based largely on expected demand for our H1N1 vaccine, we
> believe that our 2009 revenues will exceed expectations. However, due
> to uncertainty on the timing of future orders, we are not able to
> further quantify our expectations.

> Batch Release Report indicated that 4.26m H1N1 vaccine doses had been
> supplied by Sinovac as at 30 September, and will therefore be the
> figure that counts towards 3Q Income figures due to be released on 18
> November.

> Another 1.2m doses had been released by 15 October, making a total
> release of 5.46m doses out of the 11.49m Chinese Government order,
> leaving 6.03m still to be supplied. The current production capacity of
> PANFLU.1 therefore appears to be c.2.5m doses, indicating that the
> full order should be met by year end and included in final year income
> figures.

> Given a conservative estimate of c.$3 a dose being paid by the Chinese
> Government for its PANFLU.1 orders, it would seem reasonable to
> estimate a minimum year end sales of $85m-$95m an increase of approx
> 100% from the 2008 $46.5m sales figure, and 50% above the company's
> original sales estimate of $55m-$60m.

> This is indeed impressive, but looking forward the future income for
> SVA looks even more impressive, with potential only being limited by
> capacity. The capacity issue is being dealt with however, and with
> large cash reserves it is likely that SVA will expand through
> aquisition as well as organically. The licences granted to supply
> Mexico (H1N1) and Hong Kong (H5N1) are but slight, albeit very
> important, inroads that SVA is planning longer term. There is, an as
> yet unconfirmed order from Mexico for £5m H1N1 vaccine doses, that can
> only be met once the Chinese Government has given its permission which
> will not be given until January at the earliest, with stockpiling its
> own reserves takes priority.

> The granting of licences in Mexico and Hong Kong are very important
> and much more significant imo, than the current 'bonus' of H1N1
> vaccine production/orders. SVA is now becoming internationally
> respected, thanks to its fast and safe introduction of recent
> vaccines, with H5N1, H1N1 and rabies coming on stream following its
> renowned Healive, which on its own previously contributed 70% of SVA's
> sales.

> Sinovac's stated goal is to aim at supplying 2 billion people,
> including Ukraine, Mongolia , India, Korea and Southeast Asia and
> South America and other regions. This demonstrates the longer term
> potential of SVA, and that this year's estimated 100%+ increase on
> sales is but just the start. The U.S. vaccine prices are about $8-10,
> giving some idea of potential income. SVA has the advantage of being
> able to produce vaccine more cheaply than Western companies and could
> undercut prices and still enable a high profit margin. This will
> enable SVA to be favoured by developing countries where finances are
> limited. Expansion and production increase to meet demand can't happen
> overnight, but with its high cash reserve SVA is better placed than
> most to fast track the required expansion.

> There is much more, and I've only skirted the available information
> that's available through research (although research is more difficult
> on a China based company). Do your research, and you will realise that
> SVA, although attractive as a short term play, is an outstanding long
> term investment. People talk about is SVA worth $8, $10,
> $15...........at the moment, and worry about MM manipulation! If you
> do the research, it is clear, imo, that at today's share price SVA is
> an outstanding purchase. Trade it if you wish, but imo trading SVA
> will result in any profits gained will be dwarfed by the profits that
> will be made by remaining a long term holder (which also reduces to
> nil the stress levels!).

> All the above is imo. Do your own research and then enjoy the ride.

> On 3 Nov, 02:35, sakalas91 <boris.baku...@gmail.com> wrote:

> > Here is an important reminder:  Sinovac's 2nd Q Financial Results:

> > - Reaffirmation of 2009 sales projection to be $55 million to $60
> > million -
> > - H1N1 vaccine may drive additional growth -

> > BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:
> > SVA), a leading developer and provider of vaccines in China, announced
> > today its unaudited financial results for the three-month and six-
> > month periods ended June 30, 2009.

> >   Financial Highlights

> >     -- Sales for the quarter increased 21% to $20.0 million
> >     -- Sales for the six-month period increased 5% to $26.6 million
> >     -- Operating income for the quarter rose 52% to $10.7 million
> >     -- Operating income for the six-month period increased 11% to
> >        $11.3 million.
> >     -- Net income attributable to the shareholders increased 74% to
> >        $5.8 million in the second quarter, with diluted EPS of $0.14
> >     -- Cash and cash equivalents at June 30, 2009 was $46.7 million.

> > Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
> > "We are very pleased with our second quarter results, with sales up
> > 21% and net income up 74%. Our revenue growth in the quarter was
> > partly driven by increased sales of our inactivated hepatitis A
> > vaccine, Healive®, to the public market, as we worked to fulfill the
> > previously announced purchase order from China's Ministry of Public
> > Health (MOH). Sinovac fulfilled and recorded 89% of the original order
> > for $12.8 million worth of doses in the second quarter of 2009. Going
> > forward, we will continue to focus on increasing our penetration of
> > both the private and public markets.

> > Mr. Yin continued, "We remain very excited about our growth prospects
> > for 2009 and beyond. In addition to the H1N1 vaccine, we have a robust
> > pipeline of other investigational vaccines, including enterovirus 71
> > (EV 71), pneumococcal conjugated vaccine, and Japanese encephalitis.
> > Overall, our objective for the next three to five years is to have one
> > or two product candidates per year entering into clinical trials
> > beginning in 2010 and one or two products launched into the market per
> > year commencing in 2012. In addition to our organic growth strategy,
> > we have the financial flexibility to selectively pursue acquisition
> > candidates that will help to expand our product pipeline, due to $47
> > million of cash and cash equivalents on our balance sheet. Previously,
> > we projected revenues of $55 million to $60 million for the full year
> > 2009. Based largely on expected demand for our H1N1 vaccine, we
> > believe that our 2009 revenues will exceed expectations. However, due
> > to uncertainty on the timing of future orders, we are not able to
> > further quantify our expectations.

> Here is an important reminder:  Sinovac's 2nd Q Financial Results:

> - Reaffirmation of 2009 sales projection to be $55 million to $60
> million -
> - H1N1 vaccine may drive additional growth -

> BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:
> SVA), a leading developer and provider of vaccines in China, announced
> today its unaudited financial results for the three-month and six-
> month periods ended June 30, 2009.

>   Financial Highlights

>     -- Sales for the quarter increased 21% to $20.0 million
>     -- Sales for the six-month period increased 5% to $26.6 million
>     -- Operating income for the quarter rose 52% to $10.7 million
>     -- Operating income for the six-month period increased 11% to
>        $11.3 million.
>     -- Net income attributable to the shareholders increased 74% to
>        $5.8 million in the second quarter, with diluted EPS of $0.14
>     -- Cash and cash equivalents at June 30, 2009 was $46.7 million.

> Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
> "We are very pleased with our second quarter results, with sales up
> 21% and net income up 74%. Our revenue growth in the quarter was
> partly driven by increased sales of our inactivated hepatitis A
> vaccine, Healive®, to the public market, as we worked to fulfill the
> previously announced purchase order from China's Ministry of Public
> Health (MOH). Sinovac fulfilled and recorded 89% of the original order
> for $12.8 million worth of doses in the second quarter of 2009. Going
> forward, we will continue to focus on increasing our penetration of
> both the private and public markets.

> Mr. Yin continued, "We remain very excited about our growth prospects
> for 2009 and beyond. In addition to the H1N1 vaccine, we have a robust
> pipeline of other investigational vaccines, including enterovirus 71
> (EV 71), pneumococcal conjugated vaccine, and Japanese encephalitis.
> Overall, our objective for the next three to five years is to have one
> or two product candidates per year entering into clinical trials
> beginning in 2010 and one or two products launched into the market per
> year commencing in 2012. In addition to our organic growth strategy,
> we have the financial flexibility to selectively pursue acquisition
> candidates that will help to expand our product pipeline, due to $47
> million of cash and cash equivalents on our balance sheet. Previously,
> we projected revenues of $55 million to $60 million for the full year
> 2009. Based largely on expected demand for our H1N1 vaccine, we
> believe that our 2009 revenues will exceed expectations. However, due
> to uncertainty on the timing of future orders, we are not able to
> further quantify our expectations.

> Hey You allways give Positive information about Sinovac, I don't know
> how far its true. we spend lot of money on this company, its not even
> touch to $9 per/share, even flu season about to over,  What is your
> suggestion, Would you think, it will go $9 per/share in this year ??

> On Nov 2, 9:35 pm, sakalas91 <boris.baku...@gmail.com> wrote:

> > Here is an important reminder:  Sinovac's 2nd Q Financial Results:

> > - Reaffirmation of 2009 sales projection to be $55 million to $60
> > million -
> > - H1N1 vaccine may drive additional growth -

> > BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:
> > SVA), a leading developer and provider of vaccines in China, announced
> > today its unaudited financial results for the three-month and six-
> > month periods ended June 30, 2009.

> >   Financial Highlights

> >     -- Sales for the quarter increased 21% to $20.0 million
> >     -- Sales for the six-month period increased 5% to $26.6 million
> >     -- Operating income for the quarter rose 52% to $10.7 million
> >     -- Operating income for the six-month period increased 11% to
> >        $11.3 million.
> >     -- Net income attributable to the shareholders increased 74% to
> >        $5.8 million in the second quarter, with diluted EPS of $0.14
> >     -- Cash and cash equivalents at June 30, 2009 was $46.7 million.

> > Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
> > "We are very pleased with our second quarter results, with sales up
> > 21% and net income up 74%. Our revenue growth in the quarter was
> > partly driven by increased sales of our inactivated hepatitis A
> > vaccine, Healive®, to the public market, as we worked to fulfill the
> > previously announced purchase order from China's Ministry of Public
> > Health (MOH). Sinovac fulfilled and recorded 89% of the original order
> > for $12.8 million worth of doses in the second quarter of 2009. Going
> > forward, we will continue to focus on increasing our penetration of
> > both the private and public markets.

> > Mr. Yin continued, "We remain very excited about our growth prospects
> > for 2009 and beyond. In addition to the H1N1 vaccine, we have a robust
> > pipeline of other investigational vaccines, including enterovirus 71
> > (EV 71), pneumococcal conjugated vaccine, and Japanese encephalitis.
> > Overall, our objective for the next three to five years is to have one
> > or two product candidates per year entering into clinical trials
> > beginning in 2010 and one or two products launched into the market per
> > year commencing in 2012. In addition to our organic growth strategy,
> > we have the financial flexibility to selectively pursue acquisition
> > candidates that will help to expand our product pipeline, due to $47
> > million of cash and cash equivalents on our balance sheet. Previously,
> > we projected revenues of $55 million to $60 million for the full year
> > 2009. Based largely on expected demand for our H1N1 vaccine, we
> > believe that our 2009 revenues will exceed expectations. However, due
> > to uncertainty on the timing of future orders, we are not able to
> > further quantify our expectations.- Hide quoted text -

> - Show quoted text -

> Wow…now suddenly sakalas91 is the “bad guy”!!! Comrades, please!!!
> These are just opinions of regular people (like you and I), and in no
> way, shape or form the trading advice. Use your own judgment and don’t
> blame anyone for your trading decision!
> Just my 2 cents worth…

> On Nov 3, 8:44 am, Kishore <kishor...@gmail.com> wrote:

> > Hey You allways give Positive information about Sinovac, I don't know
> > how far its true. we spend lot of money on this company, its not even
> > touch to $9 per/share, even flu season about to over,  What is your
> > suggestion, Would you think, it will go $9 per/share in this year ??

> > On Nov 2, 9:35 pm, sakalas91 <boris.baku...@gmail.com> wrote:

> > > Here is an important reminder:  Sinovac's 2nd Q Financial Results:

> > > - Reaffirmation of 2009 sales projection to be $55 million to $60
> > > million -
> > > - H1N1 vaccine may drive additional growth -

> > > BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:
> > > SVA), a leading developer and provider of vaccines in China, announced
> > > today its unaudited financial results for the three-month and six-
> > > month periods ended June 30, 2009.

> > >   Financial Highlights

> > >     -- Sales for the quarter increased 21% to $20.0 million
> > >     -- Sales for the six-month period increased 5% to $26.6 million
> > >     -- Operating income for the quarter rose 52% to $10.7 million
> > >     -- Operating income for the six-month period increased 11% to
> > >        $11.3 million.
> > >     -- Net income attributable to the shareholders increased 74% to
> > >        $5.8 million in the second quarter, with diluted EPS of $0.14
> > >     -- Cash and cash equivalents at June 30, 2009 was $46.7 million.

> > > Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
> > > "We are very pleased with our second quarter results, with sales up
> > > 21% and net income up 74%. Our revenue growth in the quarter was
> > > partly driven by increased sales of our inactivated hepatitis A
> > > vaccine, Healive®, to the public market, as we worked to fulfill the
> > > previously announced purchase order from China's Ministry of Public
> > > Health (MOH). Sinovac fulfilled and recorded 89% of the original order
> > > for $12.8 million worth of doses in the second quarter of 2009. Going
> > > forward, we will continue to focus on increasing our penetration of
> > > both the private and public markets.

> > > Mr. Yin continued, "We remain very excited about our growth prospects
> > > for 2009 and beyond. In addition to the H1N1 vaccine, we have a robust
> > > pipeline of other investigational vaccines, including enterovirus 71
> > > (EV 71), pneumococcal conjugated vaccine, and Japanese encephalitis.
> > > Overall, our objective for the next three to five years is to have one
> > > or two product candidates per year entering into clinical trials
> > > beginning in 2010 and one or two products launched into the market per
> > > year commencing in 2012. In addition to our organic growth strategy,
> > > we have the financial flexibility to selectively pursue acquisition
> > > candidates that will help to expand our product pipeline, due to $47
> > > million of cash and cash equivalents on our balance sheet. Previously,
> > > we projected revenues of $55 million to $60 million for the full year
> > > 2009. Based largely on expected demand for our H1N1 vaccine, we
> > > believe that our 2009 revenues will exceed expectations. However, due
> > > to uncertainty on the timing of future orders, we are not able to
> > > further quantify our expectations.- Hide quoted text -

> > - Show quoted text -

> Thanks Art S for reiterating what I often write when posting.

> Kishore, on balance I think SVA is a good stock to own for reasons I
> have already stated.  But it also has several drawbacks, the major one
> being that its price is subject to seasonal fluctuation and market
> manipulation by Sarsan.  Art S. is right about doing your own dd and
> using your own judgment. However, your point is well-taken and should
> serve as a warning to all.  Never base your trading decisions on what
> you read on discussion boards.  They are useful in that they allow us
> to share information, which can improve our morale in difficult times
> like these.

> IMHO, SVA's price will continue to be held down until about a week
> before earnings.  When it will spike, nobody can say.

> We are all in the same boat, so I bid you and all others well.

> On Nov 3, 10:49 am, "Art S." <epagemas...@gmail.com> wrote:

> > Wow…now suddenly sakalas91 is the “bad guy”!!! Comrades, please!!!
> > These are just opinions of regular people (like you and I), and in no
> > way, shape or form the trading advice. Use your own judgment and don’t
> > blame anyone for your trading decision!
> > Just my 2 cents worth…

> > On Nov 3, 8:44 am, Kishore <kishor...@gmail.com> wrote:

> > > Hey You allways give Positive information about Sinovac, I don't know
> > > how far its true. we spend lot of money on this company, its not even
> > > touch to $9 per/share, even flu season about to over,  What is your
> > > suggestion, Would you think, it will go $9 per/share in this year ??

> > > On Nov 2, 9:35 pm, sakalas91 <boris.baku...@gmail.com> wrote:

> > > > Here is an important reminder:  Sinovac's 2nd Q Financial Results:

> > > > - Reaffirmation of 2009 sales projection to be $55 million to $60
> > > > million -
> > > > - H1N1 vaccine may drive additional growth -

> > > > BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:
> > > > SVA), a leading developer and provider of vaccines in China, announced
> > > > today its unaudited financial results for the three-month and six-
> > > > month periods ended June 30, 2009.

> > > >   Financial Highlights

> > > >     -- Sales for the quarter increased 21% to $20.0 million
> > > >     -- Sales for the six-month period increased 5% to $26.6 million
> > > >     -- Operating income for the quarter rose 52% to $10.7 million
> > > >     -- Operating income for the six-month period increased 11% to
> > > >        $11.3 million.
> > > >     -- Net income attributable to the shareholders increased 74% to
> > > >        $5.8 million in the second quarter, with diluted EPS of $0.14
> > > >     -- Cash and cash equivalents at June 30, 2009 was $46.7 million.

> > > > Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
> > > > "We are very pleased with our second quarter results, with sales up
> > > > 21% and net income up 74%. Our revenue growth in the quarter was
> > > > partly driven by increased sales of our inactivated hepatitis A
> > > > vaccine, Healive®, to the public market, as we worked to fulfill the
> > > > previously announced purchase order from China's Ministry of Public
> > > > Health (MOH). Sinovac fulfilled and recorded 89% of the original order
> > > > for $12.8 million worth of doses in the second quarter of 2009. Going
> > > > forward, we will continue to focus on increasing our penetration of
> > > > both the private and public markets.

> > > > Mr. Yin continued, "We remain very excited about our growth prospects
> > > > for 2009 and beyond. In addition to the H1N1 vaccine, we have a robust
> > > > pipeline of other investigational vaccines, including enterovirus 71
> > > > (EV 71), pneumococcal conjugated vaccine, and Japanese encephalitis.
> > > > Overall, our objective for the next three to five years is to have one
> > > > or two product candidates per year entering into clinical trials
> > > > beginning in 2010 and one or two products launched into the market per
> > > > year commencing in 2012. In addition to our organic growth strategy,
> > > > we have the financial flexibility to selectively pursue acquisition
> > > > candidates that will help to expand our product pipeline, due to $47
> > > > million of cash and cash equivalents on our balance sheet. Previously,
> > > > we projected revenues of $55 million to $60 million for the full year
> > > > 2009. Based largely on expected demand for our H1N1 vaccine, we
> > > > believe that our 2009 revenues will exceed expectations. However, due
> > > > to uncertainty on the timing of future orders, we are not able to
> > > > further quantify our expectations.- Hide quoted text -

> > > - Show quoted text -

> Here is an important reminder:  Sinovac's 2nd Q Financial Results:

> - Reaffirmation of 2009 sales projection to be $55 million to $60
> million -
> - H1N1 vaccine may drive additional growth -

> BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:
> SVA), a leading developer and provider of vaccines in China, announced
> today its unaudited financial results for the three-month and six-
> month periods ended June 30, 2009.

>   Financial Highlights

>     -- Sales for the quarter increased 21% to $20.0 million
>     -- Sales for the six-month period increased 5% to $26.6 million
>     -- Operating income for the quarter rose 52% to $10.7 million
>     -- Operating income for the six-month period increased 11% to
>        $11.3 million.
>     -- Net income attributable to the shareholders increased 74% to
>        $5.8 million in the second quarter, with diluted EPS of $0.14
>     -- Cash and cash equivalents at June 30, 2009 was $46.7 million.

> Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
> "We are very pleased with our second quarter results, with sales up
> 21% and net income up 74%. Our revenue growth in the quarter was
> partly driven by increased sales of our inactivated hepatitis A
> vaccine, Healive®, to the public market, as we worked to fulfill the
> previously announced purchase order from China's Ministry of Public
> Health (MOH). Sinovac fulfilled and recorded 89% of the original order
> for $12.8 million worth of doses in the second quarter of 2009. Going
> forward, we will continue to focus on increasing our penetration of
> both the private and public markets.

> Mr. Yin continued, "We remain very excited about our growth prospects
> for 2009 and beyond. In addition to the H1N1 vaccine, we have a robust
> pipeline of other investigational vaccines, including enterovirus 71
> (EV 71), pneumococcal conjugated vaccine, and Japanese encephalitis.
> Overall, our objective for the next three to five years is to have one
> or two product candidates per year entering into clinical trials
> beginning in 2010 and one or two products launched into the market per
> year commencing in 2012. In addition to our organic growth strategy,
> we have the financial flexibility to selectively pursue acquisition
> candidates that will help to expand our product pipeline, due to $47
> million of cash and cash equivalents on our balance sheet. Previously,
> we projected revenues of $55 million to $60 million for the full year
> 2009. Based largely on expected demand for our H1N1 vaccine, we
> believe that our 2009 revenues will exceed expectations. However, due
> to uncertainty on the timing of future orders, we are not able to
> further quantify our expectations.

> Research confirms that Chinese Government is paying SVA approx $3 per
> H1N1 vaccine. Now possible to calculate 3Q and Full Year sales. This
> figure concurs with my estimated figures - see above.

> Once Chinese Government gives permission for SVA to export an
> estimated $5-$6 price per vaccine is expected.

> On 3 Nov, 02:35, sakalas91 <boris.baku...@gmail.com> wrote:

> > Here is an important reminder:  Sinovac's 2nd Q Financial Results:

> > - Reaffirmation of 2009 sales projection to be $55 million to $60
> > million -
> > - H1N1 vaccine may drive additional growth -

> > BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:
> > SVA), a leading developer and provider of vaccines in China, announced
> > today its unaudited financial results for the three-month and six-
> > month periods ended June 30, 2009.

> >   Financial Highlights

> >     -- Sales for the quarter increased 21% to $20.0 million
> >     -- Sales for the six-month period increased 5% to $26.6 million
> >     -- Operating income for the quarter rose 52% to $10.7 million
> >     -- Operating income for the six-month period increased 11% to
> >        $11.3 million.
> >     -- Net income attributable to the shareholders increased 74% to
> >        $5.8 million in the second quarter, with diluted EPS of $0.14
> >     -- Cash and cash equivalents at June 30, 2009 was $46.7 million.

> > Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
> > "We are very pleased with our second quarter results, with sales up
> > 21% and net income up 74%. Our revenue growth in the quarter was
> > partly driven by increased sales of our inactivated hepatitis A
> > vaccine, Healive®, to the public market, as we worked to fulfill the
> > previously announced purchase order from China's Ministry of Public
> > Health (MOH). Sinovac fulfilled and recorded 89% of the original order
> > for $12.8 million worth of doses in the second quarter of 2009. Going
> > forward, we will continue to focus on increasing our penetration of
> > both the private and public markets.

> > Mr. Yin continued, "We remain very excited about our growth prospects
> > for 2009 and beyond. In addition to the H1N1 vaccine, we have a robust
> > pipeline of other investigational vaccines, including enterovirus 71
> > (EV 71), pneumococcal conjugated vaccine, and Japanese encephalitis.
> > Overall, our objective for the next three to five years is to have one
> > or two product candidates per year entering into clinical trials
> > beginning in 2010 and one or two products launched into the market per
> > year commencing in 2012. In addition to our organic growth strategy,
> > we have the financial flexibility to selectively pursue acquisition
> > candidates that will help to expand our product pipeline, due to $47
> > million of cash and cash equivalents on our balance sheet. Previously,
> > we projected revenues of $55 million to $60 million for the full year
> > 2009. Based largely on expected demand for our H1N1 vaccine, we
> > believe that our 2009 revenues will exceed expectations. However, due
> > to uncertainty on the timing of future orders, we are not able to
> > further quantify our expectations.

> Here is an important reminder:  Sinovac's 2nd Q Financial Results:

> - Reaffirmation of 2009 sales projection to be $55 million to $60
> million -
> - H1N1 vaccine may drive additional growth -

> BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:
> SVA), a leading developer and provider of vaccines in China, announced
> today its unaudited financial results for the three-month and six-
> month periods ended June 30, 2009.

>   Financial Highlights

>     -- Sales for the quarter increased 21% to $20.0 million
>     -- Sales for the six-month period increased 5% to $26.6 million
>     -- Operating income for the quarter rose 52% to $10.7 million
>     -- Operating income for the six-month period increased 11% to
>        $11.3 million.
>     -- Net income attributable to the shareholders increased 74% to
>        $5.8 million in the second quarter, with diluted EPS of $0.14
>     -- Cash and cash equivalents at June 30, 2009 was $46.7 million.

> Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
> "We are very pleased with our second quarter results, with sales up
> 21% and net income up 74%. Our revenue growth in the quarter was
> partly driven by increased sales of our inactivated hepatitis A
> vaccine, Healive®, to the public market, as we worked to fulfill the
> previously announced purchase order from China's Ministry of Public
> Health (MOH). Sinovac fulfilled and recorded 89% of the original order
> for $12.8 million worth of doses in the second quarter of 2009. Going
> forward, we will continue to focus on increasing our penetration of
> both the private and public markets.

> Mr. Yin continued, "We remain very excited about our growth prospects
> for 2009 and beyond. In addition to the H1N1 vaccine, we have a robust
> pipeline of other investigational vaccines, including enterovirus 71
> (EV 71), pneumococcal conjugated vaccine, and Japanese encephalitis.
> Overall, our objective for the next three to five years is to have one
> or two product candidates per year entering into clinical trials
> beginning in 2010 and one or two products launched into the market per
> year commencing in 2012. In addition to our organic growth strategy,
> we have the financial flexibility to selectively pursue acquisition
> candidates that will help to expand our product pipeline, due to $47
> million of cash and cash equivalents on our balance sheet. Previously,
> we projected revenues of $55 million to $60 million for the full year
> 2009. Based largely on expected demand for our H1N1 vaccine, we
> believe that our 2009 revenues will exceed expectations. However, due
> to uncertainty on the timing of future orders, we are not able to
> further quantify our expectations.

> http://www.sinovac.com/UpLoadFiles/File/Investors/Sinovac%20Investor%...

> On 3 Nov, 02:35, sakalas91 <boris.baku...@gmail.com> wrote:

> > Here is an important reminder:  Sinovac's 2nd Q Financial Results:

> > - Reaffirmation of 2009 sales projection to be $55 million to $60
> > million -
> > - H1N1 vaccine may drive additional growth -

> > BEIJING, Aug. 19 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex:
> > SVA), a leading developer and provider of vaccines in China, announced
> > today its unaudited financial results for the three-month and six-
> > month periods ended June 30, 2009.

> >   Financial Highlights

> >     -- Sales for the quarter increased 21% to $20.0 million
> >     -- Sales for the six-month period increased 5% to $26.6 million
> >     -- Operating income for the quarter rose 52% to $10.7 million
> >     -- Operating income for the six-month period increased 11% to
> >        $11.3 million.
> >     -- Net income attributable to the shareholders increased 74% to
> >        $5.8 million in the second quarter, with diluted EPS of $0.14
> >     -- Cash and cash equivalents at June 30, 2009 was $46.7 million.

> > Mr. Weidong Yin, Chairman, President and CEO of Sinovac, commented,
> > "We are very pleased with our second quarter results, with sales up
> > 21% and net income up 74%. Our revenue growth in the quarter was
> > partly driven by increased sales of our inactivated hepatitis A
> > vaccine, Healive®, to the public market, as we worked to fulfill the
> > previously announced purchase order from China's Ministry of Public
> > Health (MOH). Sinovac fulfilled and recorded 89% of the original order
> > for $12.8 million worth of doses in the second quarter of 2009. Going
> > forward, we will continue to focus on increasing our penetration of
> > both the private and public markets.

> > Mr. Yin continued, "We remain very excited about our growth prospects
> > for 2009 and beyond. In addition to the H1N1 vaccine, we have a robust
> > pipeline of other investigational vaccines, including enterovirus 71
> > (EV 71), pneumococcal conjugated vaccine, and Japanese encephalitis.
> > Overall, our objective for the next three to five years is to have one
> > or two product candidates per year entering into clinical trials
> > beginning in 2010 and one or two products launched into the market per
> > year commencing in 2012. In addition to our organic growth strategy,
> > we have the financial flexibility to selectively pursue acquisition
> > candidates that will help to expand our product pipeline, due to $47
> > million of cash and cash equivalents on our balance sheet. Previously,
> > we projected revenues of $55 million to $60 million for the full year
> > 2009. Based largely on expected demand for our H1N1 vaccine, we
> > believe that our 2009 revenues will exceed expectations. However, due
> > to uncertainty on the timing of future orders, we are not able to
> > further quantify our expectations.